Hypertension
Conditions
Brief summary
The aim of this study was to establish a registration and monitoring system for hypertension in Xinjiang from 2020 to 2030 to obtain real information about patient basic information, patient characteristics, diagnostic test patterns, treatment options, and hospitalization outcomes (including mortality). Treatment complications, hospitalization costs, and end-of-life events (death, major adverse cardiac events, mild adverse cardiovascular events) in patients with hypertension in Xinjiang; and scientific prevention strategies aimed at effectively preventing the onset of hypertension; Guidelines in clinical practice recommend, analyze and develop effective treatment strategies to optimize management and outcomes for patients with hypertension; and create cost-effective assessment systems.
Detailed description
The aim of the study is to establish a platform for monitoring, clinical research and translational medicine in Xinjiang, which aims to provide a basis for future quality improvement and research, and to promote efforts to improve the prognosis of patients with hypertension, and to translate research into improved care for patients, thereby reducing Morbidity and mortality associated with hypertension.
Interventions
OTHERStandard therapy
Individualized blood pressure reduction program
Sponsors
Xinjiang Medical University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* A patient diagnosed with primary hypertension who was admitted to the First Affiliated Hospital of Xinjiang Medical University
Exclusion criteria
* Patients with secondary hypertension, patients with liver and kidney dysfunction, * patients with mental disorders, and patients who are unwilling to participate in this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Resistant hypertension | 10 years of follow-up Resistant hypertension occurred during this period |
| Death (all-cause mortality, mortality from hypertension complications) | 10 years of follow-up deaths occurred during this period |
Secondary
| Measure | Time frame |
|---|---|
| Major adverse cardiovascular events | 10 years of follow-up deaths occurred during this period |
Countries
China
Contacts
Primary ContactXiang Xie, Phd
Outcome results
None listed